Although immunotherapy (anti‐PD‐1 or anti‐CTLA‐4 antibodies) and targeted therapy (BRAF/MEK inhibitors) have been approved for the treatment of advanced melanoma patients, only a minority of patients derive benefit.5, 6. Here, MAP2K7 is linked to melanoma.